Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

Medicine and Dentistry

• Tyrosine-Kinase Inhibitor 100%
• Pleura Effusion 100%
• Pericardial Fluid 100%
• Dasatinib 100%
• Cancer 50%
• Adverse Event 50%
• Phosphotransferase 50%
• Imatinib 50%
• Platelet Derived Growth Factor 50%
• Chronic Myelogenous Leukemia 50%
• Natural Killer Cell 50%
• Invasive Procedure 50%
• Nilotinib 50%
• Side Effect 50%

Keyphrases

• Inflammation 100%
• Tyrosine Kinase Inhibitor 100%
• Pleural Effusion 100%
• Pericardial Effusion 100%
• Dasatinib 66%
• Malignancy 33%
• Platelet-derived Growth factor-BB (PDGF-BB) 33%
• Adverse Events 33%
• Chronic Myeloid Leukemia 33%
• Nilotinib 33%
• Age of Onset 33%
• Natural Killer Cells 33%
• Invasive Procedures 33%
• Clinical Consequences 33%
• Imatinib 33%
• Kinase Inhibition 33%